IMM2510, an Anti-PD-L1/VEGF Bispecific Antibody Fusion Protein for Advanced IO-pretreated SQ-NSCLC: A Phase I Study Post date September 10, 2025 ← IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study.
Instil BioInstil Bio